Blinded independent central review analysis showed a 6.8-month improvement in median progression-free survival with sunitinib versus placebo in patients with pancreatic neuroendocrine tumors. The 5-year overall survival (OS) results continued to favor sunitinib, although not statistically significant. Adjustment for treatment crossover in the placebo arm confirmed OS benefit of sunitinib therapy.
from Cancer via ola Kala on Inoreader http://annonc.oxfordjournals.org/cgi/content/short/mdw561v1?rss=1
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου